Protara Therapeutics, Inc. announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock or, for certain purchasers, pre-funded warrants to purchase an aggregate of 1,700,000 shares of its common stock, in each case, along with warrants to purchase an aggregate of 10,843,380 shares of its common stock, in a private placement financing with certain institutional accredited investors.
April 5, 2024
· 6 min read